Prashant Reddy

Maybe just to pivot us to the other half of the industry, just for a little bit around just enabling the next generation of research and innovation, I think is the theme you mentioned at the start.

What are some of the decisions that private market, public market participants could make to

maintain, I'd say, the edge our country has in this space?

This is actually a Life Sciences and a BBM and a

pharmacy and a payer problem.

It's across the value chain.

So is that okay?

Maybe just as we close this out, are there opportunities that you're seeing at the federal or state level that could further get accelerated across the themes you mentioned?

So how achievable do you think what you've described really is?

And what do you think it will take for us to get there?

Thank you again, Matt.

Really appreciate the time today.

You know,

Fascinating conversation as always.

So thank you again.

Hopefully faster.

You've been listening to the McKinsey on Healthcare podcast.

We were joined by Matt Holt, a managing director and the president of private equity at New Mountain Capital.

For more interviews with leading experts and thought leaders across the healthcare industry, visit

Be sure to subscribe to McKinsey on Healthcare on Apple Podcasts, Spotify, or wherever you get your podcasts.